Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors
JCI Insight · 2024
DOI: 10.1172/jci.insight.166231 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2024. Verfasst von Carine Ciron und 9 weiteren Autor:innen. Beteiligte Einrichtung: Xenothera, Nantes, France. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Melanoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Heterologous polyclonal antibodies (pAb) were shown to possess oncolytic properties a century ago with reported clinical responses. More recent preclinical models confirmed pAb efficacy, though their ability to tackle complex target antigens reduces susceptibility to tumor escape. Owing to the recent availability of glyco-humanized pAb (GH-pAb) with acceptable clinical toxicology profile, we revisited use of pAb in oncology and highlighted their therapeutic potential against multiple cancer types. Murine antitumor pAb were generated after repeated immunization of rabbits with murine tumor cell lines from hepatocarcinoma, melanoma, and colorectal cancers. Antitumor pAb recognized and showed cytotoxicity against their targets without cross-reactivity with healthy tissues. In vivo, pAb are effective alone; moreover, these pAb synergize with immune checkpoint inhibitors like anti–PD-L1 in several cancer models. They elicited an antitumor host immune response and prevented metastases. The anticancer activity of pAb was also confirmed in xenografted NMRI nude mice using GH-pAb produced by repeated immunization of pigs with human tumor cell lines. In conclusion, the availability of bioengineered GH-pAb allows for revisiting of passive immunotherapy with oncolytic pAb to fight against solid tumor and cancer metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xenothera, Nantes, France.
- CRIP, Oniris, INRAE, Nantes, France.
- Nantes Université, Inserm, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France.
Zitieren
APA
Ciron, C., Morice, P., Rousse, J., Roy, P., Royer, P. J., Gauthier, O., Brouard, S., Duvaux, O., Bassissi, F., & Vanhove, B. (2024). Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors. JCI Insight. https://doi.org/10.1172/jci.insight.166231
Vancouver
Ciron C, Morice P, Rousse J, Roy P, Royer PJ, Gauthier O, et al. Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors. JCI Insight. 2024. doi:10.1172/jci.insight.166231
BibTeX
@article{Ciron2024,
author = {Ciron, Carine and Morice, Pierre and Rousse, Juliette and Roy, Patrice and Royer, Pierre-Joseph and Gauthier, Olivier and Brouard, Sophie and Duvaux, Odile and Bassissi, Firas and Vanhove, Bernard},
title = {Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors},
journal = {JCI Insight},
year = {2024},
doi = {10.1172/jci.insight.166231}
}
EUVIMED